12
Dec
2018

First Everest, Now Kilimanjaro: Climb With Me and a Great Biotech Team to Fight Cancer

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

A Trek in the Himalayas for Cancer Research
Join Me and a Biotech Team on the Trek of a Lifetime for Cancer Research
Thank You, Biotech: Kili Climb to Fight Has Crushed Its $1m Goal for Cancer Research
The Boston Cancer Summit and SF Cancer Summit. See the Agenda & Get Your Tickets